PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Annals of Oncology10.1093/annonc/mdy300.022201829viii610Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomitingJ.H. Kwon, J.-H. Kang, Y.-G. Lee, K.U. Park, H.J. An, J. Sohn, Y.M. Seol, H. Lee, H.-J. Yun, J.S. Ahn, H.J. Kimhttps://api.elsevier.com/content/article/PII:S0923753419501478?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419501478?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy300.022/26139140/mdy300.022.pdf
European Journal of Cancer Supplements10.1016/s1359-6349(05)81580-0200532371-3721287 POSTER Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy-induced nausea & vomiting after emetogenic chemotherapyhttps://api.elsevier.com/content/article/PII:S1359634905815800?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905815800?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2019.7132020523907-916Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and VomitingJin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, Keon Uk Park, Ho Jung An, Joohyuk Sohn, Young Mi Seol, Hyunwoo Lee, Hwan-Jung Yun, Jin Seok Ahn, Ji Hyun Yang, Hunho Song, Dong-Hoe Koo, Jin Young Kim, Gun Min Kim, Hwa Jung Kimhttp://e-crt.org/upload/pdf/crt-2019-713.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2019.713, http://e-crt.org/upload/pdf/crt-2019-713.pdf
SpringerPlus10.1186/s40064-016-3769-x201651Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapyToshimichi Miya, , Kunihiko Kobayashi, Mitsunori Hino, Masahiro Ando, Susumu Takeuchi, Masahiro Seike, Kaoru Kubota, Akihiko Gemmahttp://link.springer.com/content/pdf/10.1186/s40064-016-3769-x.pdf, http://link.springer.com/article/10.1186/s40064-016-3769-x/fulltext.html, http://link.springer.com/content/pdf/10.1186/s40064-016-3769-x.pdf
Annals of Oncology10.1016/s0923-7534(20)34125-9201223ix509The Efficacy of Triplet Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving Highly Emetogenic Chemotherapy: Palonosetron (PALO), Aprepitant (APR), and Dexamethasone (DEX)H. Yoshizawa, K. Sato, M. Makino, O. Kobayashi, H. Tanaka, S. Miura, S. Watanabe, J. Tanaka, H. Kagamu, N. Ichieihttps://api.elsevier.com/content/article/PII:S0923753420341259?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420341259?httpAccept=text/plain
Supportive Care in Cancer10.1007/s00520-017-3967-22017Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapyTakeshi Ioroi, Junya Furukawa, Manabu Kume, Sachi Hirata, Yuko Utsubo, Naomi Mizuta, Hideaki Miyake, Masato Fujisawa, Midori Hiraihttp://link.springer.com/content/pdf/10.1007/s00520-017-3967-2.pdf, http://link.springer.com/article/10.1007/s00520-017-3967-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00520-017-3967-2.pdf
Annals of Oncology10.1016/s0923-7534(20)32210-9201223xi88Efficacy of Triplet Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving Highly Emetogenic Chemotherapy: Palonosetron, Aprepitant, and DexamethasoneM. Hayashi, S. Miura, K. Sato, M. Makino, O. Kobayashi, H. Miyao, A. Iwashima, K. Ichikawa, J. Koshio, S. Watanabe, J. Tanaka, H. Kagamu, A. Yokoyama, I. Narita, H. Yoshizawahttps://api.elsevier.com/content/article/PII:S0923753420322109?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420322109?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdx6982018292452-458A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)L. Zhang, S. Lu, J. Feng, A. Dechaphunkul, J. Chang, D. Wang, S. Chessari, C. Lanzarotti, K. Jordan, M. Aaprohttps://api.elsevier.com/content/article/PII:S0923753419350446?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419350446?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/2/452/23980134/mdx698.pdf
Value in Health10.1016/j.jval.2014.08.22222014177A625Cost-Consequence Analysis of an Aprepitant Regimen Versus a Standard Antiemetic Regimen for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in ItalyG. Rosti, R. Ravasiohttps://api.elsevier.com/content/article/PII:S1098301514041527?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301514041527?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdu356.9201425iv520Prevention of Chemotherapy-Induced Nausea and Vomiting with a Fixed-Dose Combination of Netupitant and Palonosetron (Nepa) Following Highly Emetogenic Chemotherapy: Evaluation of Response Based on Gender and AgeP. Hesketh, K. Jordan, R. Grallahttps://api.elsevier.com/content/article/PII:S092375341952960X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375341952960X?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/25/suppl_4/iv520/9692177/mdu356.9.pdf